Mount Sinai researchers identified genes that predict a positive response to selinexor, a multiple myeloma therapy which can have serious side effects for some patients.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
